Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study
Author(s) -
Erin J. Aiello Bowles,
Robert Wellman,
Heather Spencer Feigelson,
Adedayo A. Onitilo,
Andrew N. Freedman,
Thomas Delate,
Larry A. Allen,
Larissa Nekhlyudov,
Katrina A.B. Goddard,
Robert L. Davis,
Laurel A. Habel,
Marianne Ulcickas Yood,
Catherine A. McCarty,
David J. Magid,
Edward H. Wagner,
Pharmacovigilance Study Team
Publication year - 2012
Publication title -
jnci journal of the national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.797
H-Index - 356
eISSN - 1460-2105
pISSN - 0027-8874
DOI - 10.1093/jnci/djs317
Subject(s) - trastuzumab , anthracycline , medicine , breast cancer , oncology , heart failure , generalizability theory , retrospective cohort study , cardiomyopathy , adjuvant , cancer , cardiology , psychology , developmental psychology
Clinical trials demonstrated that women treated for breast cancer with anthracycline or trastuzumab are at increased risk for heart failure and/or cardiomyopathy (HF/CM), but the generalizability of these findings is unknown. We estimated real-world adjuvant anthracycline and trastuzumab use and their associations with incident HF/CM.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom